Resource Summary Report

Generated by nidm-terms on Jul 30, 2026

BD Biosciences: LSR II Flow Cytometer

RRID:SCR_002159
Type: Tool

Proper Citation

BD Biosciences: LSR II Flow Cytometer (RRID:SCR_002159)

Resource Information

URL: https://www.bd.com/resource.aspx?IDX=17868

Proper Citation: BD Biosciences: LSR II Flow Cytometer (RRID:SCR_002159)

Description: Benchtop high-performance cell sorter with multiple lazer, detector and fluoroscrome options. Allows detection of 12 parameters (10 color conjugates, forward and sideward scatter).

Abbreviations: LSR II Flow Cytometer

Resource Type: instrument resource

Keywords: flow cytometer, instrument, equipment, hardware

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Specification URL: https://drive.google.com/file/d/1iqsXa8XNCYWutCswBRYBWluHGag0lOSx/view?usp=drivesdk

Resource Name: BD Biosciences: LSR II Flow Cytometer

Resource ID: SCR_002159

Alternate IDs: Model_Number_BD LSR II, SciRes_000152

Alternate URLs: https://fccf.sitehost.iu.edu/pdf/BDLSRIIUserGuide.pdf

Old URLs: http://www.rockefeller.edu/fcrc/pdf/BD_LSRII_Brochure_SJ-0142-00.pdf

Record Creation Time: 20220129T080211+0000

Record Last Update: 20260725T190516+0000

Ratings and Alerts

No rating or validation information has been found for BD Biosciences: LSR II Flow Cytometer.

No alerts have been found for BD Biosciences: LSR II Flow Cytometer.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at nidm-terms .

Jha V, et al. (2025) Substitution of Glutamic Acid at Position 71 of DR?1*04:01 and Collagen-Specific Tolerance Without Alloreactivity. Arthritis & rheumatology (Hoboken, N.J.), 77(5), 526.

Xue F, et al. (2025) CRISPR/Cas9 Screening Highlights PFKFB3 Gene as a Major Contributor to 5-Fluorouracil Resistance in Esophageal Cancer. Cancers, 17(10).

Katkeviciute E, et al. (2025) Bacteria-derived 3-hydroxydodecanoic acid induces a potent anti-tumor immune response via the GPR84 receptor. Cell reports, 44(3), 115357.

van der Heide V, et al. (2025) Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8+ T cells. Immunity, 58(7), 1742.

Kim AR, et al. (2025) Co-blockade of TGF? and PD-1 Reinvigorates Glioblastoma-Infiltrating CD8+ T Cells That Characteristically Upregulate TGF?RI Expression. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(15), 3306.

Wischnewski V, et al. (2025) The local microenvironment suppresses the synergy between irradiation and anti-PD1 therapy in breast-to-brain metastasis. Cell reports, 44(3), 115427.

Álvarez-Prado ÁF, et al. (2025) Cancer cell and microenvironmental rewiring by ADAR1 loss impairs glioblastoma tumor growth and extends survival. Cell reports, 44(9), 116151.

Füchsl F, et al. (2024) High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells. Nature communications, 15(1), 10520.

Radziszewska A, et al. (2024) Type I interferon and mitochondrial dysfunction are associated with dysregulated cytotoxic CD8+ T cell responses in juvenile systemic lupus erythematosus. Clinical and experimental immunology.

Rodriguez D, et al. (2024) Fractalkine isoforms differentially regulate microglia-mediated inflammation and enhance visual function in the diabetic retina. Journal of

neuroinflammation, 21(1), 42.

Nasser AM, et al. (2024) CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(14), 2996.

Rodriguez D, et al. (2024) Therapeutic Delivery of Soluble Fractalkine Ameliorates Vascular Dysfunction in the Diabetic Retina. International journal of molecular sciences, 25(3).

de Kivit S, et al. (2024) Immune suppression by human thymus-derived effector Tregs relies on glucose/lactate-fueled fatty acid synthesis. Cell reports, 43(9), 114681.

Huntington KE, et al. (2023) GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer. bioRxiv : the preprint server for biology.

Chambers C, et al. (2023) SWI/SNF Blockade Disrupts PU.1-Directed Enhancer Programs in Normal Hematopoietic Cells and Acute Myeloid Leukemia. Cancer research, 83(7), 983.

Huntington KE, et al. (2023) GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. International journal of molecular sciences, 24(13).

Dressel N, et al. (2023) Activation of the cGAS/STING Axis in Genome-Damaged Hematopoietic Cells Does Not Impact Blood Cell Formation or Leukemogenesis. Cancer research, 83(17), 2858.

Pinho AG, et al. (2023) The Central Nervous System Source Modulates Microglia Function and Morphology In Vitro. International journal of molecular sciences, 24(9).

Darrah PA, et al. (2023) Airway T cells are a correlate of i.v. Bacille Calmette-Guerin-mediated protection against tuberculosis in rhesus macaques. Cell host & microbe, 31(6), 962.

Wu Y, et al. (2023) MicroRNA-223 limits murine hemogenic endothelial cell specification and myelopoiesis. Developmental cell, 58(14), 1237.